New virus (HMPV) in china
In late 2024, China experienced a notable increase in cases of human metapneumovirus (HMPV), particularly among children under 14. HMPV is a respiratory virus that typically causes mild, cold-like symptoms but can lead to severe respiratory issues such as bronchitis or pneumonia in vulnerable populations, including young children, the elderly, and immunocompromised individuals.
The Chinese Center for Disease Control and Prevention reported that, during the week of December 16 to 22, 2024, HMPV accounted for 6.2% of positive respiratory illness tests and 5.4% of respiratory-related hospitalizations, surpassing figures for COVID-19, rhinovirus, or adenovirus during the same period.
This surge has led to crowded hospitals and increased public concern, with some drawing parallels to the early days of the COVID-19 pandemic. However, health experts emphasize that HMPV is not a new virus; it was first identified in 2001 and has a well-documented profile. Unlike COVID-19, HMPV does not pose the same level of threat due to existing partial immunity within the population and established diagnostic methods.
Neighboring countries, including Malaysia, Hong Kong, Kazakhstan, and India, have also reported cases of HMPV. In India, two infants were recently diagnosed with the virus; however, these cases are not linked to the situation in China and involve no international travel history.
In Pakistan, health authorities have noted that HMPV has been present since 2001, with sporadic cases reported over the years. The National Institute of Health is closely monitoring the situation in China and has convened meetings to assess any potential impact on Pakistan.
While the rise in HMPV cases has strained healthcare facilities in affected regions, experts advise that maintaining good hygiene practices, such as regular handwashing and avoiding close contact with infected individuals, can help prevent the spread of the virus. Currently, there is no specific treatment or vaccine for HMPV, so supportive care is the primary approach for those infected.
No comments:
Post a Comment